We are thrilled to welcome Nadia Agopyan, Ph.D., RAC, to the Neurona team as our Senior Vice President of Regulatory Affairs. Nadia brings over 20 years of experience in leading global regulatory strategy for drugs and biologics, including cell therapies. Her expertise will be invaluable as we advance our regenerative neural cell therapies through clinical development. Welcome, Nadia! We look forward to achieving great milestones together in our mission to develop life-changing therapies for neurological disorders! Learn more here: https://lnkd.in/gRh75K5B
Neurona Therapeutics
Biotechnology Research
South San Francisco, CA 4,902 followers
Building the next generation of cell-based medicines
About us
Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders. Based on a novel neural cell lineage pioneered by the company’s scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders. For more information about Neurona visit our website.
- Website
-
http://www.neuronatherapeutics.com
External link for Neurona Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, CA
- Type
- Privately Held
Locations
-
Primary
170 Harbor Way
South San Francisco, CA 94080, US
Employees at Neurona Therapeutics
-
Haydee Frost, CCRC, CCRP
In-House Clinical Research Associate, Clinical Operations and Development
-
Melvin Abara
Associate Director @ Treadwell | MBA, Quality Assurance
-
Seonok Lee, Ph.D.
Director at Neurona Therapeutics
-
Nadia Agopyan, Ph.D., RAC
Senior VP @ Neurona Therapeutics | Regulatory Affairs Certified
Updates
-
Today Neurona announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the company’s lead product candidate, NRTX-1001, which is being developed for drug-resistant mesial temporal lobe epilepsy (MTLE). The RMAT program is dedicated to advancing investigational regenerative medicines, including cell therapies, that are intended to treat, modify, reverse, or cure serious diseases where preliminary clinical evidence indicates that the regenerative medicine therapy has the potential to address unmet medical needs. Learn more about NRTX-1001 and this development in the press release here: https://lnkd.in/eJHzyZ6P #epilepsy #celltherapy
-
Director of Discovery Research at Neurona, Marina Bershteyn, Ph.D., has been invited to present a seminar titled "Development of allogeneic GABAergic inhibitory interneuron cell therapy for drug-resistant focal epilepsy" at the Cell Based Therapeutics of Brain Diseases Meeting, which is part of the Neuroscience School of Advanced Studies Challenge Workshops. Marina's presentation will outline recent clinical data and supporting preclinical data from Neurona's ongoing clinical trial of NRTX-1001 which is demonstrating the potential to significantly reduce seizure frequency in adults with unilateral mesial temporal lobe epilepsy (MTLE). Learn more about NRTX-1001 and our clinical trials here: https://lnkd.in/e37V9uf2 Learn more about the meeting here: https://lnkd.in/eVRp7Wbx
-
We are delighted to announce that Manher (AJ) Joshi, M.D., has joined Neurona as Chief Medical Officer. AJ brings a wealth of clinical development and commercialization expertise across a variety of neuro-focused indications and has extensive experience in the development of cell therapies. We look forward to his leadership as we advance our pipeline of cellular therapeutic candidates for neurological diseases, including NRTX-1001 for drug-resistant focal epilepsy. Welcome to the Neurona team, AJ! Learn more about AJ's background here: https://lnkd.in/eMjD7Tvs #epilepsy #celltherapy
-
If you are attending the Jefferies Global Healthcare Conference in New York City this week, our CEO, Cory R. Nicholas, PhD, will be hosting meetings to update investors on the most recent data from Neurona's ongoing open-label Phase 1/2 clinical trial of NRTX-1001 in adults with drug-resistant, unilateral mesial temporal lobe epilepsy (MTLE) and the Company's plans to develop its pipeline of allogeneic, off-the-shelf, regenerative neural cell therapy products. #epilepsy #celltherapy
-
If you are attending #ASGCT2024 please stop by Poster # 842 on Wednesday, May 8th when Neurona team member Brianna Feld will be presenting supporting preclinical data and the most recent clinical update from our hpsc-derived inhibitory interneuron cell therapy, NRTX-1001, which is being evaluated in an ongoing clinical trial in adults with drug-resistant focal #epilepsy.
-
At the Annual Meeting of the American Academy of Neurology ,#AAN2024, today, our CEO, Cory R. Nicholas, PhD, is presenting a clinical update on the first cohort of our ongoing Phase I/II clinical trial of NRTX-1001, which is being evaluated in people with drug-resistant focal #epilepsy. Read the details in our press release here: https://lnkd.in/e4yuHJiK
-
Looking forward to the upcoming discussion between Elias Uhlin and our cofounder and CEO, Cory R. Nicholas, PhD, as part of the ATMP World Tour, on the development and early clinical data from the ongoing Phase 1/2 clinical trial of NRTX-1001, a novel, regenerative cell therapy which is being evaluated for the treatment of mesial temporal lobe #epilepsy (MTLE). Learn more about the ATMP World Tour and how to listen to this session here: https://lnkd.in/ggS_UR6V
Can you treat epilepsy with a cellular therapy.....the early data is quite remarkable. This session of the ATMP world tour 2024 highlights the clinical activity of Neurona Therapeutics, a company pioneering cell therapy to regulate hyperexciteable brain circuitry. Their allogeneic, pluripotent derived inhibitory neurons are a true disruptor for treatment of drug resistant epilepsy. Join Elias Uhlin and Neurona CEO Cory R. Nicholas, PhD to follow the translation of this lineage/sub lineage and stage specific academic research to the clinic, and to explore the implications of this non destructive regenerative treatment for patients. https://lnkd.in/ggS_UR6V
-
On Tuesday, March 26th, Neurona employees celebrated #PurpleDay, an international initiative dedicated to increasing awareness about #epilepsy. John Hixson, MD, Neurona's senior medical director, and a neurologist and practicing epilepsy specialist, gave a fascinating presentation explaining the range of conditions experienced by his patients, the standard interventions that are currently available to them, and the work being done by Neurona to develop NRTX-1001, a regenerative cell therapy that is currently being studied as a potentially safe and effective therapeutic option for people with drug-resistant focal epilepsy.
-
Our CEO, Cory R. Nicholas, PhD, will be presenting a corporate update at the upcoming Stifel 2024 Virtual CNS Days event next week covering recently presented clinical data from Neurona's lead program NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for the treatment of drug-resistant focal #epilepsy, and Neurona's plans for 2024. His presentation, at 5:00 pm ET on Tuesday, March 19th , will be webcast and can be accessed here: https://lnkd.in/eBnTQ-uq